Aptevo Therapeutics Inc. Revenue From Contract With Customer Excluding Assessed Tax

Quick Answer

Aptevo Therapeutics Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $3.11 million for the year ending 2022.

  • Aptevo Therapeutics Inc. showed a decrease of -74.7% in Revenue From Contract With Customer Excluding Assessed Tax from 2021 to 2022.
  • This data is from Aptevo Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2024.
  • XBRL data for this metric is available from 2017 to 2022 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 6 years of available data (2017 to 2022), Aptevo Therapeutics Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 78.8%.
  • Historical annual values: Fiscal year 2022: $3.11 million | Fiscal year 2021: $12.29 million | Fiscal year 2020: $4.31 million | Fiscal year 2019: $32.42 million | Fiscal year 2018: $23.07 million | Fiscal year 2017: $14.66 million.
  • Data sourced from SEC EDGAR public filings as of June 24, 2026.

Last verified: